3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
5
Triple Negative Breast Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
1
Solid Tumors
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
14
Nivolumab
13
Sunitinib
12
Axitinib
9
cabozantinib
8
belzutifan
8
Ipilimumab
7
Everolimus
5
atezolizumab
4
Sorafenib
4
temsirolimus
3
perifosine
3
motexafin gadolinium
3
Drug Therapy
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
lenvatinib
2
entinostat
2
ciforadenant
2
belinostat
2
avelumab
2
Paclitaxel
2
Immunotherapy
2
G250 monoclonal antibody
2
Fluorouracil
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Kidney Neoplasms
×
CB-839
×
Clear all
NCT03428217
2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2
Completed
444 enrolled
15 charts